Key facts
- It has raised $25.8M; the latest was Later Stage VC in Oct 2024.
- Notable investors include Y Combinator, Nvidia, M12, Playground Global, Jude Gomila — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for 1910
- ·The full record, as it builds
Funding rounds
No funding rounds for 1910 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 1910
Developer of a drug discovery platform intended to offer small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. The company's platform offers new end-to-end drug discovery and development processes that must be reimagined from the ground up using AI, enabling clients to improve productivity and decrease failure rates across the pharmaceutical development process.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 40
- Website
- 1910.ai/
- Ownership
- Privately Held (backing)
1910 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 1910 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 1910 in its N-PORT filings yet. We sweep new filings monthly.